Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 2/20 | 0.45 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.44 |
| ▸ | JAK2 known ✓ | O60674 | 2/20 | 0.43 |
| ▸ | JAK1 known ✓ | P23458 | 2/20 | 0.43 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.41 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.40 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.40 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | FABP4 | P15090 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4184556 | 0.98 | KDM4E (0.46) | KDM4ERAB9AAGTR1FABP4GLA | |
| SCHEMBL2920235 | 0.84 | KDM4E (0.44) | KDM4ERAB9AAGTR1GLAALDH1A1 | |
| SCHEMBL27611476 | 0.84 | KDM4E (0.44) | KDM4ERAB9AAGTR1GLAALDH1A1 | |
| SCHEMBL20274413 | 0.84 | KDM4E (0.50) | KDM4ERAB9AAGTR1GLAALDH1A1 | |
| Hydrochloric Acid SCHEMBL8584876 | 0.83 | KDM4E (0.56) | KDM4ERAB9AFABP4ALDH1A1NPC1 | |
| SCHEMBL2001238 | 0.82 | FABP4 (0.48) | KDM4ERAB9AAGTR1FABP4GLA | |
| Hydrochloric Acid SCHEMBL5389527 | 0.81 | AGTR1 (0.53) | KDM4ERAB9AAGTR1ALDH1A1JAK2 | |
| SCHEMBL605325 | 0.81 | KDM4E (0.58) | KDM4ERAB9AFABP4ALDH1A1NPC1 | |
| SCHEMBL7959032 | 0.81 | ALDH1A1 (0.45) | KDM4ERAB9AALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL6088062 | 0.81 | JAK2 (0.48) | KDM4ERAB9AAGTR1FABP4GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767819-B2 | Thiazolylimidazole derivatives and their use as inhibitors of microsomal triglyceride transfer protein | MERCK PATENT GMBH (DE) | 2010-08-03 | — | — | US | disclosed |
| US-20100137601-A1 | THIAZOLYLIMIDAZOLE DERIVATIVES AN THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN | GUEDAT PHILIPPE | 2010-06-03 | — | — | US | disclosed |
| US-7674803-B2 | Thiazolypiperidine derivatives as MTP inhibitors | MERCK PATENT GMBH (DE) | 2010-03-09 | — | — | US | disclosed |
| EP-1636218-B1 | THIAZOLYLPIPERIDINE DERIVATIVES AS MTP INHIBITORS | MERCK PATENT GMBH (DE) | 2009-03-25 | — | — | EP | disclosed |
| US-20080214610-A1 | Thiazolylimidazole Derivatives and Their Use as Inhibitors of Microsmal Triglyceride Transfer Protein | MERCK PATENT GMBH (DE) | 2008-09-04 | — | — | US | disclosed |
| US-20070054939-A1 | Thiazolypiperidine derivatives as mtp inhibitors | MERCK PATNET GMBH (DE) | 2007-03-08 | — | — | US | disclosed |
| EP-1711180-A1 | THIAZOLYLIMIDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN | MERCK PATENT GmbH (DE) | 2006-10-18 | — | — | EP | disclosed |
| EP-1636218-A1 | THIAZOLYLPIPERIDINE DERIVATIVES AS MTP INHIBITORS | MERCK PATENT GmbH (DE) | 2006-03-22 | — | — | EP | disclosed |
| WO-2005074934-A1 | THIAZOLYLIMIDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF MICROSMAL TRIGLYCE RIDE TRANSFER PROTEIN | MERCK PATENT GMBH (DE) | 2005-08-18 | — | — | WO | disclosed |
| WO-2005003128-A1 | THIAZOLYLPIPERIDINE DERIVATIVES AS MTP INHIBITORS | MERCK PATENT GMBH (DE) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137601-A1 | THIAZOLYLIMIDAZOLE DERIVATIVES AN THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN | MTTP, CETP, CYP4F2 | AGTR1 1491/4885GLA 2601/4885JAK2 1806/4885 |
| US-20080214610-A1 | Thiazolylimidazole Derivatives and Their Use as Inhibitors of Microsmal Triglyceride Transfer Protein | MTTP, CETP, MTR | AGTR1 1837/4885GLA 1996/4885JAK2 1221/4885 |
| US-20070054939-A1 | Thiazolypiperidine derivatives as mtp inhibitors | MTTP, CETP, APOB | AGTR1 149/4885GLA 1514/4885JAK2 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.